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Worldwide the hepatitis B virus (HBV) is responsible for a
large proportion of all forms of liver disease and is probably
the most frequent cause of chronic viral disease in man. The
economic and human cost of HBV is further exacerbated by
its association with hepatocellular carcinoma (Hee), one of
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Structure
HBV is classified as a member of the family Hepadnaviridae
(Fig. 1)."3 HBV is a small, spherical virus and has a diameter
of 42 nm with a 27 nm inner core corresponding to the
highly jmmunogenic hepatitis B core antigen (HBcAg).' The
outer coat consists of a waxy lipophilic material and the
three envelope proteins, termed hepatitis B surface antigen
(HBsAg). These large, middle-sized and small HBsAg
proteins are derived from a common open reading frame by
alternate use of three stop codons.' Hepatitis B e antigen
(HBeAg) is a soluble non-structural, enigmatic antigen which
is often detected in the blood of patients infected with
replicating HBV which results in massive viral load in the
blood. Both HBe and HBc are derived from the same
section of HBV DNA but the HBe transcript contains an
additional 29 codons in phase and upstream of the HBc;
these encode a secretory or signal peptide.,,6 This addition
facilitates entry into the hepatocyte endoplasmic reticulum
where the HBe is processed and secreted.' Viral DNA
mutations resulting in the cessation of HBeAg production
are thought to occur by the insertion of a stop codon in the
pre-HBc sequence.6The X protein is most probably a
regulatory factor and may serve as a transcription activator.'
The virus also contains a circular DNA molecule which is
partially double-stranded and is associated with a DNA
polymerase protein. Possibly, as a consequence of the very
small size of the HBV genome, the coding capacity has
been enhanced by the use of overlapping open reading
frames and multiple usage of the available DNA.5.6 A happy
consequence of this phenomenon is that the DNAs of
several HBV isolates were sequenced over a decade ago
and have subsequently been cloned in Escherichia coli,
yeast and several mammalian cell lines.
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Fig. 1. Structure of the hepatitis B virus. Excess viral proteins are
seen as spheres and tubules.
Replication of HBV within hepatocytes and other cells in
man appears dependent on virion attachment via the'pre-S
region, entry, genome uncoating and the interaction of
specific and nonspecific (e.g. steroid receptors) transcription
factors of that cell which may interact with the HBV DNA
binding sequences,>,6 Unlike the retroviruses, the DNA of
HBV does not need to be integrated into the host cell
genomic DNA for viral replication to occur.9 Transcription of
mRNA is highly regulated and results in the formation of the
various envelope, core, X, reverse transcriptases, RNAses,
polymerases and the HBV pol protein.6",9 These in addition
generate the minus HBVDNA strand and the incomplete
plus strand, which uniquely contains a segment of RNA.
The polymerase and core proteins co-ordinate packaging
within the cell nucleus.6Integration of usually defective or
degenerate HBV DNA into the host genome occurs in a
random fashion and may result in the generation of
truncated viral proteins, 'neoproteins' or uncontrolled cell
growth by the interaction with cell cycle control proteins.
Three types of particle may be seen on electron
microscopy in serum from patients with acute or chronic
hepatitis B infection. These are the Dane particles
representing the complete viral particle, and the 22 nm
diameter spheres and tubules which represent excess
virally-coded substance proteins. The surface of the Dane
particles display HBsAg and the spheres and tubules consist
of HBsAg.'o This excess HBsAg can be used to provide
useful vaccine products."
Laboratory diagnosis
As there are a number of tests available for the diagnosis of
HBV infection and immunity, it is important to rationalise
one's approach to the individual clinical setting." Broadly
speaking, there are tests for screening, for specific diagnosis
and for prognosis. These laboratory tests include analysis of
viral proteins (e.g. HBsAg) or the immunological humoral
response against these antigens (e.g. anti-HBs). More
sophisticated tests involve the analysis and determination of
viral HBV DNA in biological fluids or tissues.
The analysis and measurement of HBsAg is the single
most important test and is widely available. The standard
methods employed are radio-immunoassay (RIA) and
enzyme immunoassay (EIA); both are available in
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commercial kit form and are suitable for automation. These
tests are cheap, rapid and accurate. The detection limit for
most assays is around 0,02 - 1 ng/ml. The confirmed finding
of HBsAg in the blood or other biological fluids is diagnostic
of HBV infection but does not indicate the duration of
infection or the replicative state of the virus. HBV vaccines
which are administered intramuscularly contain HBsAg
bound to aluminium hydroxide and thus do not produce
detectable antigenaemia. It is important to remember that
the absence of detectable HBsAg does not exclude the
potential for HBV infection. This is particularly important in
the context of fulminant liver failure.
The next most important from a clinical perspective is the
anti-HBc test which is an excellent confirmatory test in the
individual who is HBsAg positive; it can also serve as an
additional screening test to determine past exposure or
immunity to HBV. The presence of IgM anti-HBc is highly
suggestive of acute infection but may also be positive (albeit
in lower titre) in individuals with active replicative chronic
HBV infection. The major indication for the use of the anti-
HBs assay is to determine the efficacy of immunisation;
when performed in a quantitative manner, this test also
provides information on the need for booster immunisations.
Tests for HBeAg are used as a surrogate marker for active
HBV replication and thus potential viral infectivity. This
surrogate marker is, however, unreliable in certain parts of
the world (e.g. Mediterranean areas) where 'HBeAg minus'
mutants are a significant problem. 7•13 The most accurate and
definitive tests are the determinations of HBV DNA by
dot/slot blotting, liquid hybridisation assays or polymerase
chain reaction (PGR). A positive result in any of the above is
a precondition of HBV infectivity. Results are expressed
either as picograms of HBV DNA per ml or as HBV genome
equivalents - where 1 pg corresponds to roughly 3 x 10'
genomes. Optimised and reliable assays allow detection
down to the range of 5 - 10 pg/ml of HBV DNA. PGR
techniques have much rower levels of detection with
sensitivities down to 10 - 100 HBV DNA genome equivalents
per sample. Endogenous HBV DNA polymerase activity may
be assayed on well-preserved plasma samples, from which
HBV has been concentrated through sucrose gradients, and
should be regarded primarily as a research tool.1<
The assays are further explained and illustrated in the
context of both acute and chronic HBV infection later in this
article.
Epidemiology
The incubation period of HBV infection is 60 - 180 days.
Laboratory tests for hepatitis B have confirmed the
importance of parenteral transmission and the infectivity of
blood products. However, hepatitis B is not spread
exclusively by blood and blood products. HBV infection is
more prevalent in individuals living under poor socio-
economic conditions. Long-term asymptomatic carriers of
the virus are the main source of infection in the community.
There is a huge reservoir of carriers worldwide."·16
Sexual transmission of hepatitis B is well recognised. At
very high risk are male homosexuals and individuals with
mUltiple sexual partners. HBsAg has been found not only in
blood, but also in saliva, menstrual and vaginal discharges,
seminal fluid and serous exudates. These have all been
implicated in the spread of infection. Transmission of HBV
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may result from accidental inoculation of minute amounts of
blood or fluids contaminated with blood (such as may occur
during medical, surgical and dental procedures), use of
inadequately sterilised syringes and needles, intravenous
and percutaneous drug abuse, tattooing, earpiercing, nose-
piercing, acupuncture, laboratory accidents and accidental
inoculation with razors and toothbrushes.""·
In certain parts of the world, additional factors may play a
role. These include traditional tattooing, scarification, ritual
circumcision and perhaps repeated bites by blood-sucking
insects, although the latter mode of transmission remains
unproven and of uncertain epidemiological significance.
Hepatitis B may also be transmitted by carrier mothers to
their babies during the perinatal period. This vertical
transmission appears to be important in south-east Asia
where the risk of infection may reach 50 - 60% or more.
There is also a substantial risk of perinatal infection if the
mother has acute hepatitis B in the second or third trimester
of pregnancy or within 2 months of delivery. Although
hepatitis B virus can affect the fetus in utero, this is
uncommon and appears to occur in less than 5% of cases.
In contrast to countries like Taiwan, the incidence in Africa,
Greece and Hong Kong is higher in children than neonates.
In this horizontal spread, infection in the first year of life is
rare. However, in certain rural areas of South Africa large
numbers of children are infected between 3 and 10 years of
age. The same areas have extremely high incidences of
HGG with an average age of onset in the late twenties.
Geographical distribution
An estimated 300 million people are chronically infected with
HBV. HBV infection is present on all continents and almost
every country in the world. Sub-saharan Africa, south-east
and far-east Asian countries and the coastal belt of
Greenland are most affected. The rate of serum HBsAg
expression in screened individuals varies from a low of
0,1 - 0,5% in western Europe to a high of 8 - 15% in Africa
and the Far East. The prevalence of past and present HBV
virus infection as determined by the presence of antibody to
HBsAg is higher, ranging from 4 - 6% in the low-prevalence
areas to 70 - 95% in Asia and Africa. Several seroprevalence
studies undertaken in South Africa show distinct racial and
social stratification of risk. Rural communities appear to be
at greater risk of exposure and chronic viral infection.
Figures for exposure are around 70% and chronic HBsAg
carriage approximately 5 - 10%.
HBV in children
Although the predominant clinical manifestations are usually
observed in adulthood, infection with HBV in areas of high
endemicity is most commonly established in the neonatal
period, infancy or early childhood"s.l. the latter being most
important in South Africa.
The risk of chronic HBV infection in children appears to be
inversely related to the age of initial infection. Transmission
of HBV from an infected mother to her baby during birth
(perinatal or so-called 'vertical transmission') results in a risk
of persistent infection of between 70% and 90%. This
declines with increasing age, when children have a risk of
horizontal transmission of 60% during the second year of
life and 10% by the age of 6 years.
-
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Fig. 2. Serological profile of a typical case of acute hepatitis B.
percutaneous route in minute quantities of blood, e.g in
scarification practices or ear-piercing, both of which are
frequent procedures. Less obvious instances include the
passage of HBV through skin abrasions or rashes. Non-
cutaneous routes of transmission have been difficult to
document but the majority of cases are presumed to be
secondary to ingestion of contaminated secretions possibly
as a consequence of hand-mouth contact. Even airborne
particles may contain HBV and infection via the respiratory
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The clinical expression of acute HBV infection is extremely
variable and ranges from a fulminant disease (which is rare) to
subclinical infection, which is very common. Hepatocyte
damage appears to be mediated by the host immune
response, predominantly by cytotoxic T cells and natural killer
cells. HBV, per se, is probably not cytopathic but this:point is
controversial.'· Jaundice, preceded by nausea, anorexia and
vomiting, appears in about 20 - 50% of patients, and.a minor
influenza-like syndrome may occur, particularly in children.
Clinical features which may point to H8V include a long
prodromal period, arthralgia and skin rashes. The diagnosis of
HBV infection entails the use of laboratory tests which show
increased serum aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) activity, and must be
confirmed in every case by demonstration of the appropriate
hepatitis B serological markers.
The serological profile of a typical case of acute hepatitis
8 is shown in Fig. 2. HBsAg is detectable for about 3
months. Following the disappearance of H8sAg, anti-H8s
appears after a lag period of 3 weeks. Antibodies directed
against HBc appear and remain positive early on in the
disease. Anti-HBs and anti-HBc persist for years after the
patient has recovered and constitute the most lasting
evidence of previous H8V infection. IgM anti-HBc
disappears at or before 6 months, when the patient recovers
from acute hepatitis 8. Total and IgM anti-HBc are present
during the 'window' period after HBsAg is lost but before
anti-HBs antigen appears. Anti-HBe develops after the
disappearance of H8eAg. In cases of presumed acute H8V
infection where the standard viral markers are negative
during the 'window' phase, the IgM anti-HBc test becomes
invaluable in establishing the diagnosis and thus indicating
the family members' need for prophylactic therapy.
In the far eastern Asian area of high endemicity, perinatal
infection is common and accounts for a significant
proportion of chronic infection in adults. In these areas, up to
one half of pregnant women have high levels of circulating
HBV as indicated by the presence of HBeAg or HBV DNA.
Infection of the neonate is thought to occur at the time of
delivery either by percutaneous entry through skin abrasions
or by the ingestion of blood; transplacental transmission is
uncommon. In other areas of high endemicity, such as Africa
and the Middle East, perinatal transmission is much less
common. This may be a consequence of decreased serum
HBeAg expression in chronically infected, parturient mothers.
In Africa, toddlers and young children are at high risk of
contracting HBV. The exact mechanism of transmission at
this young age remains obscure; various postulated
percutaneous and oral routes remain to be proven. Infection
may occur within families, usually either from siblings or the
mother, by percutaneous or other forms of exposure. In
several studies, transmission from outside the family may
have accounted for up to one half of the total infection rate,
which is frequently over 60%. Infection in infants and young
children is usually subclinical, making them a source of
infection for other young children.
In areas with intermediate rates of HBV infection (India,
South America and eastern Europe), transmission occurs in
all age groups but is more common among older children and
adolescents. Icteric acute hepatitis B with arthralgia is more
usual with adult-onset infection and may result in severe
illness and, occasionally, death. However, early childhood
infection is considered to contribute most significantly to the
pool of 2 - 7% of adults with chronic HBV infection.
With the established improvements in socio-economic
factors and advanced health care in the developed Western
world, the prevalence of chronic infection in adults is around
1 - 2%. Here spread of HBV occurs primarily among
adolescents or adults as a consequence of intimate sexual
contact or other activities that result in transmission of
biological fluids, such as intravenous drug use. Although
only a small fraction of infection in areas of low endemicity
occur in infants and young children, these still account for
about one-third of cases of chronic infection in adults in
these populations.
Delta super-infection and other liver
diseases
Chronic infection with HBV predisposes that individual to
chronic infection with the hepatitis D virus (HDV or delta
agent) which may result in severe hepatitis and progression
to liver disease." HDV infection appears to have comparable
modes of transmission to HBV but inexplicably has a very
low prevalence in southern Africa. Alcohol abuse and iron
overload are likewise associated with more accelerated liver
disease in those individuals who have HBV markers.
Further considerations on modes of
HBV transmission
HBV is an extremely hardy virus and can survive extremes of
temperature and exposure to many chemical agents. The
virus is found in almost all body fluids or secretions, often in
high concentrations and may survive up to 6 months at
room temperature. The virus is readily transmitted via the
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Fig. 3. Typical case of chronic hepatitis B infection.
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Outcome of chronic HBV infection
Chronic HBV infection may produce an asymptomatic carrier
state (with an increased risk of HCC) or chronic hepatitis
with the potential to develop cirrhosis in up to 55% of
patients with severe histological changes, including active
inflammation and hepatocellular necrosis. The terms
'persistent' or 'active' hepatitis are often misleading and are
being phased out in favour of a new approach, in which the
nature of the chronic hepatitis is characterised by a
description of the histological changes in the context of the
serological and molecular biological evidence for HBV
replication as described above.
Another potential complication of chronic HBV infection is
primary liver carcinoma or HCC. Several studies have shown
integration of HBV DNA into the genome of human
hepatoma cells. The risk of developing liver cancer with
chronic hepatitis B virus infections is 42 times greater than
that of the general population in Western countries. In the
East, the lifetime risk of developing liver cancer may be up
to 50% in patients with chronic hepatitis B virus infection."·21
A small percentage of patients with chronic HBV infection
may develop extrahepatic manifestations such as
polyarteritis nodosa, glomerulonephritis, cryoglobulinaemia,
peripheral neuropathy'and marrow hypoplasia or even
aplasia. These conditions are thought to be related to the
formation of immune complexes or to other poorly
characterised reactions.
Treatment of chronic HBV infection
The rationale for antiviral treatment of chronic HBV infection
is that even mild forms of liver injury may progress during
episodes of reactivation,22 that there is an increased risk of
hepatocellular carcinoma,8-21 and that untreated patients
serve as a reservoir of infection's". The goals of treatment
therefore are to diminish infectivity of the host, to normalise
liver inflammation and improve symptomatology. This effect
may be predicted by the sustained disappearance of
markers of HBV virus replication!3
Of all the agents which have been used to treat chronic
type B virus hepatitis, alpha interferon (IFN) offers the most
promise. While IFN is usually well tolerated in clinically
compensated patients with chronic hepatitis B, there are
insufficient data about its efficacy and safety in patients with
decompensated forms of the disease. Steroid priming
should never be used in this group of patients because of
the risk of further decompensation. Such variables as the
pretreatment level of circulating HBV'DNA and amino-
transferase levels, degree of histological activity, sexual
lifestyle and HIV status of the patient influence the response
to treatment.23
Approximately 40% of patients lose HBeAg-positivity and
become anti-HBe-positive following standard courses of
treatment, compared with a spontaneous seroconversion
rate of approximately 10% per annum." The long-term
benefits of this treatment are still being assessed but in
several instances total clearance of the HBV infection has
been c1aimed.23
More information is needed on the treatment of patients
who are HBeAg-negative and are infected with mutant forms
of HBV. Individuals with mild to moderate decompensated
disease, HBV carriers with chronic delta infection and
children present their attending physicians with difficult
therapeutic decisions. Studies are also needed to address
whether early treatment of individuals with persistent viral
replication 6 - 12 weeks after the onset of acute hepatitis,















: : : : : : : : : : : : : : : : HBeAg : : : : : : : : : : : : .




Outcome of acute HBV infection
Most adults with acute HBV infection recover fully within 6
months. Approximately 5 - 10% progress to chronic HBV
infection. In contrast, 30 - 40% of children and about 90%
of neonates with acute HBV infection become chronically
infected.
Risk factors for chronicity of infection include gender
(males are at greater risk), age at the time of infection and
whether immunosuppression is concurrent. HBV infection
manifests as clinical hepatitis more commonly in adults than
children. Since age is also associated with the risk of
chronicity, subclinical HBV infection is also associated with
an increased risk of chronicity. Chronic carriers of HBV may
typically have a mild or asymptomatic initial episode of




By definition, patients with HBsAg persisting for longer than
6 months and HBeAg persisting for longer than 3 months
are chronic carriers. Carriers may be symptomatic (fatigue,
malaise) or healthy. In symptomatic carriers with chronic
disease, HBsAg and HBeAg, and DNA from HBV are usually
present in serum or liver. So-called 'healthy' carriers usually
produce HBsAg alone and, on most occasions, do not have
evidence of active viral replication.
The serological profile of a typical case of symptomatic
chronic hepatitis B is shown in Fig. 3. In this patient markers
of active viral replication, HBeAg and HBV DNA were
present for almost 5 years. At about 5 years after the onset
of disease seroconversion to the non-replicative state
occurred. Seroconversion is associated with disappearance
of HBeAg and HBV DNA. The development of anti-HBe may
suggest the cessation of active viral replication although, as
in this case, HBsAg may still be produced. This is, however,
an unstable situation. Individuals may relapse and again
develop markers of viral replication. Abortive
seroconversions are also documented with transient flares of
hepatitis, unaccompanied by loss of HBeAg.
-
SAMJ Volume 84 No. 8 August 1994
Prevention
Although there is still uncertainty about modes of HBV .
infection in areas of high endemicity, epidemiological studies
indicate that full immunisation with plasma-derived or
recombinant HBsAg vaccines, as part of national
immunisation programmes, viz. EPI, prior to 1 year of age,
should interrupt the major horizontal routes of infection.
The prevention of perinatal infection also requires the
administration of HBV hyperimmune globulin at birth.
Booster immunisations may also be required to prevent
infection in late childhood and in young adults."
Current recommendations by the World Health
Organisation and the Centers for Disease Control are for the
universal immunisation of infants in all geographical areas,
irrespective of endemicity. It is unfortunate that, despite the
availability of safe and increasingly cheaper vaccines there IS
still widespread apathy and even reluctance to implement
these recommendations for non-economic factors. For
example, despite the availability of safe and effective
vaccines for over a decade, the incidence of hepatitis B
infection in the USA has increased by one-third with a
postulated 300 000 new infections annually. In developing
countries, particularly in Africa, economic factors and
population numbers probably preclude the implementation
of effective mass immunisation against HBV at current HBV
vaccine prices. It is hoped that the anticipated redistribution
of medical resources and the greater emphasis on primary
health care in the 'new South Africa' facilitate the earlier
introduction of HBV immunisation.
Surveillance
Passive surveillance of hepatitis B through routine
notification has been a legal requirement for more than a
decade in South Africa. In 1990, the asymptomatic HBsAg-
positive carrier state was also made notifiable. Hepatitis B is
substantially under-reported but the reporting rates in some
parts of South Africa have been remarkably steady, enabling
the reliable interpretation of trends in the incidence rate of
HBV infection.25 Some countries have successfully
implemented sentinel surveillance programmes for HBV
infection.
Laboratory data on HBV infection serve as a useful
adjunct to notification data. Laboratories which are able to
identify repeat specimens on patients can provide useful
data on the number of cases of acute hepatitis B occurring
in their catchment area. in addition, histopathology
laboratories can provide data on the number of cases of
hepatocellular cancer.
Finally, serological screening programmes in high-risk
settings, e.g. mental institutions and in the general
population, can provide estimates of the prevalence of
exposure to HBV and the HBV carrier rate.
Immunisation
Passive immunisation
Hepatitis B immunoglobulin is prepared from plasma
samples with high titres of anti-HBs. This preparation may
confer temporary passive immunity and is useful for post-
exposure prophylaxis. The major indication for the
administration of this immunoglobulin is a single exposure to
HBV, e.g. in cases where blood containing the virus is
inoculated, ingested or splashed onto mucous membranes
and the conjuctiva. Doses of 250 - 500 international units
have been used effectively. The immunoglobulin should be
administered as early as possible after exposure, preferably
within 48 hours. There appears to be little benefit from the
administration of the immunoglobulin more than 7 days after
exposure to the virus. It is recommended that two doses be
given 30 days apart. The recommended adult dosage is
about 3 ml and the dose in the newborn infant 1 - 2 ml. The
immunoglobulin is given by deep intramuscular injection.
Active immunisation is essential for long-term protection.
Active immunisation
Active immunisation against hepatitis B is required .for
groups who are at high risk and do not have serolQ"gical
evidence of past or present HBV infection. These include
individuals requiring repeated transfusions of blood,'or blood
products, prolonged inpatient treatment, frequent tissue
penetration or repeated arterial or venous access, and
patients with natural or acquired immunodeficiency or with
malignant disease. Viral hepatitis is an occupational hazard
among health care personnel and the staff of institutions for
the mentally disabled. High rates of HBV infection occur in
intravenous drug abusers, homosexuals and commercial sex
workers. The immune response to current hepatitis vaccines
is good in the young but may be poor in immuno-
compromised patients and elderly persons.25.26
Specific issues in HBV vaccination
Vaccines currently available in South Africa consist of
plasma-derived or recombinant yeast-produced HBsAg.
These vaccines are safe, immunogenic and effective.
Ideally, vaccines are administered by intramuscular injection
into the deltoid muscle at 0, 1 and 6 months. There is no
risk of HIV or of other hepatitis virus transmission. In
protective efficacy studies, the plasma-derived and yeast-
derived vaccines appear to be equivalent. A variable
proportion of healthy individuals may lose protective levels
of anti-HBs about 5 years after the first vaccine dose. Most,
but not all, of these individuals appear to be protected
against HBV infection. Booster doses are not currently
recommended routinely but should be strongly considered
for individuals who remain in high-risk categories. Hypo-
responders, who may be .identified by post-vaccination
anti-HBs testing, may respond to revaccination.
Intradermal administration of one-tenth the usual dose of
HBV vaccine induces anti-HBs in most recipients, but the
peak response and duration of protection appear to be less
than those achieved by intramuscular administration.
Intradermal administration of booster inoculation remains to
be evaluated. The rapid induction of anti-HBs with an
accelerated HBV vaccination schedule at 0,1 and 2 months
may have potential for post-exposure prophylaxis. A
schedule of vaccination applicable to the EPI programme is
suitable for mass immunisation in the developing world.
Here HBV vaccine would be given together with OPT at 6
weeks, 10 weeks and 14 weeks of age.
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Other vaccines include polypeptides containing specific
HBV-antigenic determinants. Clinical trials of polypeptide
vaccines are in progress. Hybrid virus vaccines for HBV
utilising recombinant vaccinia viruses have been developed.
These vaccines have certain theoretical advantages in that a
single strain of vaccinia may be designed to present
antigens characteristic of several viral diseases
simultaneously. However, at present, the use of vaccinia
virus remains experimental. Other recombinant viruses being
investigated as vectors for hepatitis vaccines include
adenoviruses and polioviruses, which may be effective when
given by mouth.
The potential for the generation of vaccine-induced
escape mutants in neonates born to HBV-infected mothers
exists" but may be preventable by alterations in the
recombinant vaccines.
Conclusion
A major concern in southern Africa is to control hepatitis B
virus infection and thus prevent the appalling sequelae of
chronic infection. Universal vaccination of infants in high-risk
areas in South'Africa will be an important step in the
reduction of liver disease in our country.
The introduction of a national hepatitis B vaccination
programme in South Africa is imminent. This policy must be
supported by the political will to control HBV infection. This
entails the provision of adequate resources for vaccination
and surveillance, as well as general public health measures
aimed at preventing transmission.
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Hepatitis C - a South
African perspective
Michael D. Voigt, Heidi Smuts
The existence of non-A, non-B (NANB) hepatitis was
established in the 1970s, when accurate serological tests
allowed exclusion of hepatitis A and B viruses as the cause
of most cases of post-transfusion hepatitis.' The term
'hepatitis C' was coined after molecular cloning of nucleic
acid from highly infectious sera of chimpanzees2 identified
an RNA virus as the primary cause of post-transfusion
hepatitis (PTH). Sequence analysis and expression of the
RNA has shown it to be closely related to the flavi- and
pestiviruses. It has marked genomic variability which may
affect its biological and immunological characteristics, is
transmitted parenterally and sporadically, by as yet
unidentified routes, and causes chronic indolent liver
disease in 50 - 75% of infected patients. It is associated
with hepatocellular carcinoma, glomerulonephritis,
cryoglobulinaemia, auto-immune liver disease, lymphocytic
sialadenitis and porphyria cutanea tarda. Up to 500 million
people worldwide may be infected with hepatitis C virus
(HCV),3 and many questions about the disease remain
unanswered. Therapy is still largely ineffective and our
current understanding of the long-term natural history, our
methods of diagnosis, therapy, prevention and immunisation
are suboptimal.
Virology of HeV
HCV was first obtained by screening the products of
approximately 1 million c-DNA clones expressed in
bacteriophage vectors, with serum from patients with
NANB PTH! The sequence of the first clone identified
(5-1-1) encoded a 55 amino acid peptide containing an
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